# US 12,594,287 B2 · Human milk oligosaccharide for improving health of intestinal microenvironment and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,287 B2
- Document ID: US12594287B2
- Status: Granted
- Kind: B2
- Application number: 18/006,776
- Filed: 2021-01-27
- Published: 2023-09-14
- Granted: 2026-04-07
- Earliest claimed: 2020-11-30
- Assignees: Inner Mongolia Yili Industrial Group Co., Ltd.; Inner Mongolia Dairy Tech Res Institute Co Ltd
- Applicants: Inner Mongolia Yili Industrial Group Co., Ltd.; Inner Mongolia Dairy Tech Res Institute Co Ltd
- Inventors: Wendan Wang; Ignatius Man-Yau Szeto; Biao Liu
- Web page: https://patentgrep.com/patent/US12594287B2

## CPC

- A23L 2/39: Dry compositions
- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A23L 33/125: containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates (indigestible substances A23L33/21)
- A23L 33/21: Addition of substantially indigestible substances, e.g. dietary fibres
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 35/20: Milk; Whey; Colostrum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides human milk oligosaccharide for improving the health of intestinal microenvironment and the use thereof. Specifically, the present disclosure provides the use of human milk oligosaccharide, especially the fucosyl-based oligosaccharide 2′-FL or 3-FL in the preparation of a food for improving the health of the intestinal microenvironment, wherein the improving the health of the intestinal microenvironment includes: functioning as prebiotics in the intestinal system that are used by intestinal flora to produce gas, lowering pH to maintain the health of the intestinal microenvironment, and/or reducing branched chain fatty acids such as isobutyric acid and/or isovaleric acid. The human milk oligosaccharide of the present disclosure is used to be added into infant foods (including infant formula powder, supplementary food, and nutritional supplements), and nutritional supplements or foods for children at the age of 3 years or older, adolescents and adults, and has broad application prospects.

## Claims

### Claim 1

A method for reducing the production of isobutyric acid and/or isovaleric acid in the distal colon of an infant, comprising:
administering to the infant in need a food comprising an effective amount of human milk oligosaccharide 2′-fucosyllactose (2′-FL) or 3′-fucosyllactose (3-FL) to reduce the production of isobutyric acid and/or isovaleric acid in the distal colon of the infant”, wherein the food is an infant formula powder.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the food is used for reducing the production of isobutyric acid in the distal colon; the human milk oligosaccharide is 2′-FL or 3-FL.

### Claim 3 (depends on 2)

The method according to claim 2, wherein
the effective amount of 2′-FL used in the food is 14.2 mg/100 g powder to 3182.2 mg/100 g powder in the milk powder, or 0.02 g/L to 4.2 g/L in terms of liquid milk; or
the effective amount of 3-FL used in the food is 14.2 mg/100 g powder to 1515.3 mg/100 g powder in the milk powder, or 0.02 g/L to 2.0 g/L in terms of liquid milk.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the food is used for reducing the production of isovaleric acid in the distal colon; the human milk oligosaccharide is 2′-FL or 3-FL.

### Claim 5 (depends on 4)

The method according to claim 4, wherein
the effective amount of 2′-FL used in the food is 14.2 mg/100 g powder to 3182.2 mg/100 g powder in the milk powder, or 0.02 g/L to 4.2 g/L in terms of liquid milk; or
the effective amount of 3-FL used in the food is 14.2 mg/100 g powder to 1515.3 mg/100 g powder in the milk powder, or 0.02 g/L to 2.0 g/L in terms of liquid milk.

### Claim 6 (depends on 2)

The method according to claim 2, wherein
the effective amount of 2′-FL used in the food is 70.9 mg/100 g powder to 1818.4 mg/100 g powder, or 0.1 g/L to 2.4 g/L in terms of liquid milk; or
the effective amount of 3-FL used in the food is 70.9 mg/100 g powder to 1515.3 mg/100 g powder, or 0.1 g/L to 2.0 g/L in terms of liquid milk.

### Claim 7 (depends on 2)

The method according to claim 2, wherein
the effective amount of 2′-FL used in the food is 70.9 mg/100 g powder to 1515.3 mg/100 g powder, or 0.1 g/L to 2.0 g/L in terms of liquid milk; or
the effective amount of 3-FL used in the food is 70.9 mg/100 g powder to 757.7 mg/100 g powder, or 0.1 g/L to 1.0 g/L in terms of liquid milk.

### Claim 8 (depends on 4)

The method according to claim 4, wherein
the effective amount of 2′-FL used in the food is 70.9 mg/100 g powder to 1818.4 mg/100 g powder, or 0.1 g/L to 2.4 g/L in terms of liquid milk; or
the effective amount of 3-FL used in the food is 70.9 mg/100 g powder to 1515.3 mg/100 g powder, or 0.1 g/L to 2.0 g/L in terms of liquid milk.

### Claim 9 (depends on 4)

The method according to claim 4, wherein
the effective amount of 2′-FL used in the food is 70.9 mg/100 g powder to 1515.3 mg/100 g powder, or 0.1 g/L to 2.0 g/L in terms of liquid milk; or
the effective amount of 3-FL used in the food is 70.9 mg/100 g powder to 757.7 mg/100 g powder, or 0.1 g/L to 1.0 g/L in terms of liquid milk.